1.
Nagy L, Kao HY, Chakravarti D, et al. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell. 1997;89(3):373-80.
1.
Vetere A, Marsich E, Di Piazza M, Koncan R, Micali F, Paoletti S. Neurogenin3 triggers beta-cell differentiation of retinoic acid-derived endoderm cells. Biochem J. 2003;371(Pt 3):831-41. doi:10.1042/BJ20021524.
1.
Kozono S, Lin Y-M, Seo H-S, et al. Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 2018;9(1):3069. doi:10.1038/s41467-018-05402-2.
1.
Ashok A, Naaz S, Kota LN, et al. Does retinoic acid reverse cell cycle dysregulation in Alzheimer’s disease lymphocytes?. Asian J Psychiatr. 2019;39:174-177. doi:10.1016/j.ajp.2018.08.010.
1.
Jijon HB, Suarez-Lopez L, Diaz OE, et al. Intestinal epithelial cell-specific RARα depletion results in aberrant epithelial cell homeostasis and underdeveloped immune system. Mucosal Immunol. 2018;11(3):703-715. doi:10.1038/mi.2017.91.
1.
Yang D, Luo W, Wang J, et al. A novel controlled release formulation of the Pin1 inhibitor ATRA to improve liver cancer therapy by simultaneously blocking multiple cancer pathways. J Control Release. 2018;269:405-422. doi:10.1016/j.jconrel.2017.11.031.
1.
Frumm SM, Fan ZP, Ross KN, et al. Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. Chem Biol. 2013;20(5):713-25. doi:10.1016/j.chembiol.2013.03.020.